2013-12-14 09:07:39 - Recently published research from GlobalData, "EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022", is now available at Fast Market Research
With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease (KDOQI, 2007; Zimmet et al., 2001). When uncontrolled diabetes persists for 15 to 25 years, the blood vessels in the kidneys are damaged, resulting in abnormal amounts of proteins, including albumin, leaking into the urine (ADA, 2013; CDA, 2012; NHS, 2011; NKUDIC, 2013). Because diabetic nephropathy is a complication of diabetes, and at least 90% of all diabetic cases are type 2 diabetes, the risk factors and common comorbidities for type 2 diabetes are also considered to be the same for diabetic nephropathy. The major risk factors for type 2 diabetes are family history, advancing age, obesity, and gestational diabetes.
Hypertension and dyslipidemia are also the most commonly-occurring comorbidities in people with diabetic nephropathy (GlobalData, 2013b).
According to GlobalData's forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. There were 14.03 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM, there will be 19.87 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM by 2022, with an annual growth rate (AGR) of 4.16% during the forecast period.
Full Report Details at
- www.fastmr.com/prod/752892_epicast_report_diabetic_nephropathy_e ..
* The diabetic nephropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic nephropathyin the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the presence of comorbid hypertension.
* The diabetic nephropathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to Get this Report
* Develop business strategies by understanding the trends shaping and driving the global diabetic nephropathy market.
* Quantify patient populations in the global diabetic nephropathy market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic nephropathy therapeutics in each of the markets covered.
Report Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Poor glycemic control elevates the risk of diabetic nephropathy
3.3 Global Trends
3.4 Epidemiological Forecast for Diabetic Nephropathy (2012-2022)
3.4.1 Forecast Methodology
3.4.2 Sources Used
3.4.3 Sources Not Used
3.5 Epidemiological Forecast for Diabetic Nephropathy (2012-2022)
3.5.1 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes
3.5.2 Forecast Assumptions and Methods - Diabetic Nephropathy
3.6 Epidemiology Forecast for Diabetic Nephropathy (2012-2022)
3.6.1 Total Prevalent Cases of Diabetic Nephropathy
3.6.2 Total Prevalent Cases of Diabetic Nephropathy by Age
3.6.3 Total Prevalent Cases of Diabetic Nephropathy by Sex
3.6.4 Total Prevalent Cases of Comorbid Hypertension in Total Diabetic Nephropathy
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Epidemiology and Health Policy
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
List of Tables
1.1 List of Tables
Table 1: Classification of Patients Based on the Levels of Albuminuria for the Three Standard Tests
Table 2: 7MM, Sources of the Total Prevalence Data Used in the Analysis of Diabetic Nephropathy
Table 3: 7MM, Sources Excluded from the Analysis of Diabetic Nephropathy
Table 4: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages ≥40 Years, N, 2012-2022
Table 5: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, Row (%), 2012
Table 6: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages ≥40, N, Row (%), 2012
List of Figures
1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages ≥40 Years, N, 2012-2022
Figure 2: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, 2012
Figure 3: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages ≥40 Years, N, 2012
Figure 4: 7MM, Total Prevalent Cases of Comorbid Hypertension in Total Prevalent Cases of Diabetic Nephropathy, Both Sexes, Ages ≥40 Years, N, 2012
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.